Pfizer Gets AAV Capsid Rights From Voyager For Gene Therapy R&D
Executive Summary
Deal Snapshot: Pfizer has 12 months to evaluate a pair of AAV capsids from Voyager’s TRACER platform for use as delivery mechanisms in gene therapy candidates for neurologic and CV indications.
You may also be interested in...
Deal Watch: Bristol Accesses Tech Platforms From SyntheX, Autolus
Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.
Sandrock Joins Voyager As CEO To Advance New Gene Therapy Technology Into The Clinic
The former Biogen executive will succeed interim CEO Michael Higgins, who will continue as chairman.
Ex-Novartis Exec Unveils Neurodegeneration Gene Therapy Start-Up AviadoBio
AviadoBio believes it can overcome barriers to making gene therapy work in neurodegenerative diseases, and its new CEO knows what it takes to make a commercial success in the field.